FDA Approves Sacituzumab Govitecan for First-Line Metastatic Triple-Negative Breast Cancer The U.S. Food and Drug Administration (FDA) has granted approval for sacituzumab govitecan (Trodelvy) as a first-line treatment for patients …
Tag:
carcinoma
-
-
Surgical Delays of 91 Days or More Linked to Worse Outcomes in Early-Stage Vulvar Melanoma A study published in the *Journal of the American Academy of Dermatology* found that delays …
-
Circulating tumor DNA (ctDNA) testing is a rapidly evolving tool in oncology, used to detect molecular residual disease after cancer treatment. While these liquid biopsies can identify cancer markers before …
-
Mastering the Medical Oncology OPE: SEOM’s Comprehensive Update Program Preparing for the Public Employment Offer (OPE) in Medical Oncology requires a rigorous, structured approach to a vast amount of clinical …
-
Bioengineered Chewing Gum Shows Promise in Reducing Oral Microbes Linked to Cancer Researchers at the University of Pennsylvania School of Dental Medicine have developed a bioengineered chewing gum that targets …
-
Understanding the Role of Pseudogene-Derived lncRNAs in Cancer Stem Cells Recent research is shedding light on the complex regulatory mechanisms that drive tumor growth and treatment resistance. At the center …
-
EVA1A: A Novel Target for Metabolic Dysfunction-Associated Steatotic Liver Disease Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing global health concern …
-
Olaparib Receives Reimbursement for Advanced Pancreatic Cancer with BRCA Mutations The Italian Medicines Agency (AIFA) has approved the reimbursement of olaparib, a PARP inhibitor, for the maintenance treatment of patients …
-
GLP-1s and Tirzepatide: Weighing Benefits Against Emerging Risks Widely used medications like GLP-1 receptor agonists (GLP-1RAs) and tirzepatide have become popular for weight loss and diabetes management. While offering significant …
-
Novel Score Predicts Liver Cancer Risk with 93% Accuracy Researchers have developed a new machine-learning model that predicts the risk of liver cancer, specifically hepatocellular carcinoma (HCC), with 93% accuracy. …
Newer Posts